Incyte Corporation Stock News

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress.

The Federal Reserve's decision on interest rates will impact the short-term outlook of the economy. However, even with higher-for-longer interest rates, drug discovery moves on.

Incyte (INCY) declines on potential competition for lead drug Jakafi from Ojjaara for the treatment of intermediate or high-risk myelofibrosis.

Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK, +0.11% blood-cancer treatment, Ojjaara, that wil

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street es

Incyte Corp on Tuesday reported second-quarter profit and revenue above Wall Street estimates as demand for its blood cancer drug Jakafi and skin disorder drug Opzelura picked momentum.

Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.

Incyte Corp said on Tuesday its experimental drug to treat a skin condition in children between the age of two to twelve met the primary goal in a late-stage study.

ARCH, EQBK and INCY have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2023.

Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.

Incyte (INCY) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.55 per share a year ago.

Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.

Incyte (INCY) gets EC approval for Opzelura (cream formulation of ruxolitinib) for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indi

Micron Technology and Charles Schwab were among the top S&P 500 stock performers on Monday. Expedia was a notable loser.